Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SLC34A1 | Q06495 | 8/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14434720 | 0.84 | LMNA (0.44) | PDE4DMAPT | |
| SCHEMBL5904534 | 0.77 | PDE4D (0.70) | PDE4DPDE4BMAPTSLC34A1P2RY12 | |
| SCHEMBL13600092 | 0.75 | RAB9A (0.35) | KDM4EMAPTSLC34A1 | |
| SCHEMBL2199963 | 0.74 | PDE4D (0.62) | PDE4DPDE4BSLC34A1P2RY12ALDH1A1 | |
| SCHEMBL2201823 | 0.73 | PDE4D (0.75) | PDE4DPDE4BMAPTSLC34A1P2RY12 | |
| SCHEMBL5801416 | 0.73 | PDE4D (0.69) | PDE4DPDE4BKDM4EMAPTSLC34A1 | |
| SCHEMBL2201286 | 0.73 | PDE4D (0.67) | PDE4DPDE4BKDM4EMAPTP2RY12 | |
| SCHEMBL123446 | 0.73 | PDE4D (0.67) | PDE4DPDE4BKDM4EMAPTSLC34A1 | |
| SCHEMBL6070203 | 0.72 | PDE4D (0.63) | PDE4DPDE4BKDM4EMAPTSLC34A1 | |
| SCHEMBL1111621 | 0.72 | CYP1A2 (0.49) | KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987036-A1 | HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093520-A1 | HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | CCR5, CXCR1, CXCR3 | PDE4D 1266/4885PDE4B 1647/4885KDM4E 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.